It is demonstrated that co-treatment with bromodomain extra-C terminal domain inhibitors and HDAC inhibitors, including mocetinostat, decreases breast cancer cell viability by the induction of ubiquitin-specific protease 17 (USP17) [78]. This evidence concerns the gene USP17L9P and breast carcinoma.